CDER Expands New Review Scheme

FDA's Center for Drug Evaluation and Research is expanding the use of new review procedures that it has been phasing in over the last two years. As of Oct. 1, the start of the federal government's fiscal year, NDAs for all new molecular entities (NMEs), as well as all original BLAs and efficacy supplements for new or expanded indications, will be processed using the 21st Century Review procedure.

The new procedures incorporate planning of post-market safety requirements early

Read the full 778 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE